Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

pureMHC

pureMHC?uq=2zON1W4M
2003 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
$2M LATEST DEAL AMOUNT
1 INVESTORS
Description

Provider of a technology platform intended to be used for disease-specific target identification. The company's platform develops antibodies that mimic the specificity of T-cell receptors in the immune system, enabling healthcare practitioners to avail breakthrough therapeutic target discovery and validation with further drug development applications.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 7500 Rialto Boulevard
  • Building 2, Suite 260
  • Austin, TX 78738
  • United States

+1 (512) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore pureMHC’s full profile, request a free trial.

pureMHC Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC 18-Jun-2008 $2M 000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

pureMHC Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Texas Emerging Technology Fund Venture Capital Minority 000 0000 000000 0

pureMHC Executive Team (5)

Name Title Board
Seat
Contact
Info
Kris Looney President
Jane Yacuik Ph.D Director, Operations
William Hildebrand Ph.D Co-Founder and Chief Scientist – Target Discovery
Thomas Harlan Chief Executive Officer

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »